Introduction

Few scientific breakthroughs have reshaped modern medicine as dramatically as lipid nanoparticles (LNPs). Once a niche area in nucleic acid delivery research, these tiny lipid assemblies became the cornerstone of the world’s COVID-19 response. When Pfizer/BioNTech and Moderna deployed their mRNA–LNP vaccines in record time, they not only helped curb a global pandemic—they unveiled a powerful new therapeutic platform. The underlying chemistry of these nanoparticles—ionizable lipids, phospholipids, cholesterol, and PEG-lipids assembled to safely ferry RNA into cells—was hardly new. It reflected decades of incremental discovery in academia and industry that finally converged under the urgency of COVID-19.

The pandemic, however, was not the true beginning of LNP therapeutics. The first approved LNP drug, Patisiran (ONPATTRO®), reached the market in 2018 as a pioneering siRNA therapy for hereditary transthyretin-mediated amyloidosis, developed by Alnylam Pharmaceuticals. That milestone proved that RNA medicines could be safely and reproducibly delivered in humans. Two years later, the same fundamental lipid architecture powered the first mRNA vaccines—Pfizer/BioNTech’s Comirnaty® and Moderna’s Spikevax®—which received emergency use authorization in late 2020 and full FDA approvals in 2021–2022. In 2024, Moderna’s mRNA-1345, a vaccine for respiratory syncytial virus (RSV), became the first non-COVID mRNA–LNP vaccine approved for older adults. Altogether, at least five LNP–RNA therapeutics—one siRNA drug, three COVID-19 vaccines, and one RSV vaccine—have now been approved by the FDA or EMA, underscoring how far the field has come in less than a decade.

The COVID-19 era did more than validate the science—it built a lasting foundation for RNA manufacturing and delivery. Global players like Moderna and Samsung Biologics rapidly expanded end-to-end production capacity, while national hubs such as the UK’s Oxfordshire mRNA center established long-term infrastructure for large-scale formulation and distribution. Parallel advances in automated and continuous LNP manufacturing further improved scalability and reproducibility. This industrial and regulatory groundwork now underpins a vibrant entrepreneurial ecosystem—one that is re-imagining lipid chemistry, RNA design, and therapeutic applications beyond vaccines.

Dozens of emerging companies are now building on this foundation, expanding LNP technologies into new directions—from protein-replacement therapies and gene editing to oncology and immunotherapy. These startups are developing diverse lipid libraries, novel RNA architectures, and targeted delivery systems designed to reach tissues beyond the liver. In parallel, the investment landscape for RNA and nanoparticle platforms has surged, driven by venture capital, pharma collaborations, and strategic acquisitions.

Against this backdrop, we take a data-driven look at how startups are shaping the next era of LNP and RNA therapeutics. Using datasets from PitchBook and SEC filings, we mapped the ecosystem of firms driving RNA and LNP innovation—analyzing their technology novelty, therapeutic focus, clinical maturity, and funding trajectory to uncover where innovation is accelerating and where bottlenecks remain. Together, these insights reveal a field in rapid transition: from the emergency-driven breakthroughs of COVID-19 to a deliberate, diversified, and data-guided pursuit of RNA medicines that reach far beyond vaccines.

Scientific Overview of Lipid Nanoparticles

Lipid nanoparticles (LNPs) are small, engineered carriers built to deliver nucleic acids into cells safely and efficiently. They form spontaneously when lipids are mixed with RNA under controlled conditions, producing nanoscale particles that can encapsulate genetic material and protect it from degradation. Despite their apparent simplicity, LNPs rely on a carefully balanced formulation of four components (Figure 1): cationic/ionizable lipids, which bind and condense RNA and become positively charged inside cells to aid endosomal escape; helper lipids, which provide structural integrity; cholesterol, which improves membrane fluidity and particle stability; and PEG-anchored lipids, which prevent aggregation and extend circulation time. This modular design has made LNPs one of the most adaptable non-viral delivery systems available.

Figure 1. Schematic of lipid nanoparticle (LNP) composition and RNA cargo formats. LNPs are composed of ionizable (or cationic) lipids, helper phospholipids, cholesterol, and PEG-anchored lipids that self-assemble to encapsulate RNA and enable cellular delivery. The platform can carry multiple RNA cargo types, including linear messenger RNA (mRNA), circular RNA (circRNA), and self-amplifying RNA (saRNA), each offering distinct expression kinetics and durability.

LNPs have become foundational to RNA medicine because they solve several longstanding challenges in the delivery of nucleic acids. RNA molecules cannot cross cell membranes unaided and are rapidly degraded in vivo, and early delivery systems often failed due to poor stability, immunogenicity, or inefficient uptake. LNPs overcome many of these barriers: they are non-integrating, do not rely on viral vectors, can be manufactured at scale, and have shown favorable safety profiles across multiple approved products including siRNA therapies and mRNA vaccines. Together, these attributes established LNPs as a practical and extensible delivery platform rather than a niche solution.

Much of today’s innovation focuses on optimizing three major dimensions of this platform: LNP design, delivery/targeting, and RNA cargo. On the lipid side, research efforts center on designing new ionizable lipids with improved potency, biodegradability, and endosomal escape properties. These features help ensure that RNA can be delivered efficiently into cells, released where it can function, and cleared safely from the body without long-term buildup.

Developers are also creating targeting moieties—ligands, peptides, antibodies, and small-molecule anchors—that can be displayed on the particle surface to guide LNPs to tissues outside the liver, a long-standing limitation of conventional formulations. These strategies, collectively referred to as LNP targeting and tropism engineering, aim to expand delivery into the lung, CNS, immune cells, muscle, and tumors by altering particle composition or exploiting endogenous transport pathways. As targeting improves, LNPs are increasingly used to deliver gene-editing machinery—including CRISPR nucleases, base editors, and prime editors—offering the potential for durable or permanent correction of genetic diseases without viral vectors.

Parallel advancements are occurring on the RNA cargo itself (Figure 1). Traditional messenger RNA (mRNA) encodes proteins transiently and has become the most widely recognized RNA modality. Circular RNA (circRNA) introduces a closed-loop architecture that resists exonuclease degradation and enables longer-lived protein expression. Self-amplifying RNA (saRNA) includes replicase sequences that allow it to copy itself inside cells, enabling strong expression at orders of magnitude lower doses—an appealing property for vaccines and immunomodulatory therapies. 

Together, advancements in lipid chemistry, targeted delivery, and RNA construct engineering explain why LNPs remain central to the future of genetic medicine. By enabling the safe and tunable delivery of increasingly sophisticated RNA payloads, LNPs continue to push beyond vaccines toward a new class of programmable therapeutics capable of transient protein expression, durable gene modulation, or even one-time genomic correction. The sections that follow examine how startups are pursuing these innovations across geographies, therapeutic areas, clinical stages, and funding environments.

Geographically Mapping the Emerging LNP and RNA Innovation Landscape

Building on the scientific foundations of lipid nanoparticles and RNA engineering, we next examined how these technologies are translating into company formation, geographic concentration, and technical focus across the startup ecosystem. We identified 122 startups centered on lipid nanoparticle (LNP) and RNA innovation (Figure 2). 

Figure 2. Geographic distribution of RNA and LNP startups. Map of 122 RNA and LNP-focused startups identified using PitchBook data. Companies are concentrated in the United States (67) and Canada (12), with smaller clusters across China, Europe, and East Asia. Because PitchBook primarily captures North American venture activity, Chinese and Indian innovators are likely underrepresented.

Because this dataset was derived from PitchBook, it primarily reflects North American activity, where most venture-backed company formation data are captured. Accordingly, the United States (67) dominates the landscape, followed by Canada (12) and several smaller clusters across Western Europe and East Asia. This distribution highlights how North America currently leads in translating RNA and LNP research into commercial pipelines, particularly in areas such as targeted delivery, construct optimization, and in vivo cell engineering. However, numerous Chinese and Indian companies are also advancing LNP chemistry, RNA therapeutics, and large-scale manufacturing, though these are underrepresented in PitchBook’s venture database. In addition, while contract development and manufacturing organizations (CDMOs) and other technology providers play an essential role in enabling RNA production at scale, these companies were excluded from this analysis to focus specifically on innovation-driven startups developing proprietary RNA payloads or delivery technologies. 

Overall, this geographic pattern reflects both the maturity of North American venture ecosystems and the emergence of strong Asian innovation nodes outside the scope of traditional Western venture data sources.

Innovation Areas within the LNP and RNA Space

To understand where innovation in RNA and lipid nanoparticle (LNP) therapeutics is actually happening, we grouped startups by the primary technical bottleneck or capability they are advancing within the RNA–LNP stack (Figure 3). Rather than organizing companies by disease area or funding stage, this framework highlights how different teams are pushing the platform forward—whether through manufacturing infrastructure, delivery chemistry, molecular payload design, or computational discovery. These categories help contextualize differences in technical maturity, capital intensity, and translational timelines across the ecosystem.

Figure 3. Innovation landscape across RNA and LNP startups.  Tree map of 122 emerging companies grouped by primary innovation area, spanning CDMO / Tools & Manufacturing, Gene Editing, LNP Targeting & Tropism, RNA Construct Optimization, In Vivo Cell Engineering, LNP Lipid Chemistry Innovation, Circular RNA Platforms, Non-LNP Delivery Modalities, and AI / Computational Design. Numbers indicate the number of companies in each category

At the foundation of the ecosystem is CDMO / Tools & Manufacturing (31), which forms the industrial backbone enabling GMP-scale RNA–LNP production. Vernal Biosciences offers end-to-end mRNA-to-LNP workflows under GMP, while Precision NanoSystems (PNI), now part of Cytiva, supplies NanoAssemblr microfluidic systems widely used across R&D and clinical manufacturing. T&T Scientific complements this landscape with scalable mixers and characterization tools, supporting formulation development without operating GMP facilities directly.

Beyond manufacturing, several innovation areas define the next wave of RNA medicine. Gene Editing (18) focuses on delivering CRISPR and base-editing machinery via LNPs, tightly coupling delivery performance with editing outcomes. Beam Therapeutics advances base editing using non-viral LNPs, initially targeting the liver while building high-throughput screening platforms to expand tropism. Verve Therapeutics delivers editor mRNA and guide RNA via LNP to inactivate PCSK9 for durable LDL-C reduction, representing one of the clearest clinical use cases for in vivo editing. Intellia Therapeutics established first-in-human proof-of-concept for systemic LNP–CRISPR delivery with NTLA-2001 for ATTR, a major de-risking milestone for the modality.

A closely related category, LNP Targeting & Tropism (17), addresses one of the field’s most persistent challenges: delivery beyond the liver. These companies develop lipid chemistries and ligand-based systems that bias biodistribution toward specific tissues. ReCode Therapeutics developed the SORT-LNP platform to tune lipid composition toward lung delivery, with RCT2100 now in clinical testing for cystic fibrosis. GenEdit emphasizes ligand-directed delivery and broad extrahepatic screening, while Hopewell Therapeutics focuses on rational lipid design to reach immune and solid-tumor compartments. Although the technical approaches differ, the shared goal is precise, tissue-specific delivery.

Advances in targeting directly enable In Vivo Cell Engineering (9), where RNA–LNP payloads program immune or stromal cells directly inside the body rather than through ex vivo manipulation. Capstan Therapeutics leads this category with CPTX2309, which delivers CAR instructions to CD8 T cells in vivo for autoimmune disease, leveraging immune-cell tropism and transient expression. Nammi Therapeutics pursues related strategies in in situ immune reprogramming, illustrating how targeted delivery and RNA payload design are converging toward programmable cell therapies without manufacturing-intensive workflows.

At the molecular level, RNA Construct Optimization (15) focuses on improving RNA stability, translation efficiency, and expression durability. Gritstone bio advances self-amplifying RNA (saRNA) to drive durable T-cell responses in oncology and infectious disease settings. Replicate Bioscience applies self-replicating RNA to vaccines and metabolic disease, with validation from large pharmaceutical partners. Combined Therapeutics emphasizes mRNA design and adjuvanting strategies to broaden immune responses in vulnerable populations.

Within this space, Circular RNA Platforms (7) represent a fast-rising, more specialized subfield. Orna Therapeutics develops its oRNA® platform to enable enhanced stability and sustained expression, positioning circRNA–LNP systems as potential alternatives to some cell-therapy use cases. RiboX Therapeutics has advanced RXRG001 (circRNA-FGF2) into the clinic for radiation-induced xerostomia, demonstrating near-term regenerative applications.

On the delivery side, LNP Lipid Chemistry Innovation (7) and Non-LNP Delivery Modalities (12) focus on expanding the vehicle itself. Acuitas Therapeutics provides clinically validated LNPs that underpin multiple approved or late-stage products and continue to expand into gene-editing payloads. AexeRNA, now acquired by BioNTech, contributed next-generation lipid designs to the broader mRNA ecosystem. In parallel, non-LNP carriers pursue alternative materials strategies: SiSaf develops Bio-Courier® hybrid nanoparticles with improved stability; Eascra Biotech engineers Janus-base nanoparticles for delivery to difficult tissues such as cartilage; and QurCan Therapeutics develops TERP nanoparticles targeting the CNS via dual blood–brain barrier transport.

Finally, AI / Computational Design (6) is an emerging but compounding force across the ecosystem. Mana.bio integrates high-throughput formulation and screening with machine learning to design tissue-targeted LNPs, while Nanite Bio uses its SAYER™ platform to computationally design polymer nanoparticles for RNA and DNA delivery. In both cases, computational tools shorten iteration cycles and expand the chemical and design space beyond what traditional experimentation alone can achieve.

Breakdown of Therapeutic Indications

To understand how advances in lipid nanoparticle chemistry and RNA engineering translate into clinical focus, we examined the lead therapeutic indications pursued by emerging RNA and LNP-focused companies (Figure 4). This view highlights where RNA delivery is currently most tractable, how different RNA modalities are being matched to disease biology, and which areas of unmet need are attracting sustained innovation.

Figure 4. Distribution of lead therapeutic indications across RNA and LNP startups. Pie chart showing the primary therapeutic focus of emerging RNA and LNP-focused companies. Oncology represents the largest category, followed by rare and genetic diseases, infectious diseases and vaccines, and neurology/CNS. Smaller but notable areas include autoimmune and inflammatory diseases, cardiovascular disease, ophthalmology, metabolic or endocrine disorders, and other indications.

Oncology (25) represents the largest concentration of activity. In this category, RNA and LNP technologies are being used to encode tumor antigens, immune-stimulatory factors, or regulators of oncogenic pathways. Abogen Biosciences is developing mRNA–LNP therapeutics across oncology and infectious diseases, leveraging proprietary lipid formulations designed to support immune activation. Anima Biotech takes a distinct approach by modulating mRNA translation to selectively suppress disease-driving proteins in cancer cells. Together, these strategies illustrate how RNA medicines can either direct immune responses or regulate protein expression within malignant cells, reflecting broader momentum in tumor immunology.

Rare and genetic diseases (21) form the second-largest indication group, dominated by programs focused on RNA editing, mRNA replacement, or gene-writing strategies for monogenic disorders. Airna is advancing RNA repair technologies designed to correct pathogenic transcripts at the RNA level, while Averna Therapeutics focuses on RNA editing approaches for haploinsufficiency disorders, where partial restoration of gene function may provide therapeutic benefit. 

Infectious diseases and vaccines (11) remain a significant focus beyond the COVID-19 pandemic. Acuitas Therapeutics plays a foundational role by supplying clinically validated LNP formulations used in multiple approved mRNA vaccines. Arcturus Therapeutics has advanced self-amplifying RNA (saRNA) vaccines for COVID-19 and influenza into clinical development, using dose-sparing constructs to support durable immune responses. These programs underscore how RNA–LNP platforms continue to offer advantages in rapid antigen adaptation and scalable manufacturing.

Neurology and central nervous system (CNS) disorders (8) represent an emerging but increasingly active frontier. Ascidian Therapeutics is developing RNA exon-editing technologies aimed at correcting large or complex genetic mutations implicated in neurological disease, while Papillon Biosciences pairs RNA payload design with delivery innovations to overcome challenges in neural delivery. The presence of multiple CNS programs reflects growing confidence that advances in targeting chemistry and RNA repair approaches may help enable effective RNA delivery to the CNS.

Smaller but notable categories include autoimmune and inflammatory diseases (6), cardiovascular disease (2), ophthalmology (1), and metabolic or endocrine disorders (1). Although fewer in number, these programs illustrate the expanding scope of RNA therapeutics as delivery challenges are addressed. Abivax is advancing RNA-modulating approaches in immune-mediated disease, while Dropshot Therapeutics is exploring RNA-based strategies for cardiovascular indications, highlighting early efforts to extend RNA delivery into tissues with historically limited therapeutic access.

Overall, the distribution of lead indications shows that RNA and LNP technologies have moved well beyond vaccines into oncology, rare disease, CNS disorders, and immune-mediated conditions. While oncology and genetic diseases continue to dominate, the growing presence of CNS, autoimmune, and cardiovascular programs suggests that improvements in delivery chemistry and targeting are beginning to unlock therapeutic areas that were previously difficult to reach. Collectively, these trends point toward a next phase of RNA medicine focused on applying increasingly precise, programmable RNA tools to diseases with high unmet need.

Funding Stage and Clinical Maturity

Having examined where RNA and lipid nanoparticle technologies are being applied therapeutically, the next question is how these ambitions translate into clinical progress and capital formation. Across biotechnology more broadly, company financing has long been observed to track clinical maturity, with early-stage capital supporting preclinical platform risk and later-stage funding tied to asset-level clinical execution.

Within RNA and LNP-focused companies, this alignment is especially clear (Figure 5). At the Seed stage, companies are universally preclinical, reflecting a focus on foundational delivery and RNA-engineering challenges rather than defined therapeutic candidates. Work at this stage typically centers on developing new ionizable lipids, next-generation LNP architectures, or early mRNA and self-amplifying RNA stabilization strategies. Examples such as Genvax Technologies, Incisive Genetics, and NanoCell Therapeutics are primarily establishing technical feasibility and platform differentiation. As a result, early investors in these companies are largely backing novel delivery science and chemical innovation rather than near-term clinical data.

Figure 5. Funding stage and clinical development status of RNA and LNP companies. Stacked bar chart showing the number of companies at each clinical stage—preclinical, Phase 1, Phase 2, Phase 3, and commercial—stratified by funding status, including Seed, Series A, Series B, Series C, acquired, public, and bankrupt companies.

By Series A, the emphasis shifts toward technologies that are sufficiently mature to support first-in-human studies. Companies at this stage have typically identified a clear mechanistic advantage and a plausible therapeutic application, even if the underlying platform remains broad. Ascidian Therapeutics, Therorna, and Anima Biotech illustrate this inflection point, where platform innovations—ranging from RNA exon editing to engineered RNA constructs and translation-modulating small molecules—have progressed beyond proof-of-concept and into defined clinical programs. Series A financing thus reflects a transition from validating technology to testing biology in patients.

Series B marks a further shift from platform-first narratives to explicitly program-driven value creation. Companies such as Nammi Therapeutics, Strand Therapeutics, and Replicate Bioscience continue to develop differentiated RNA or delivery platforms, but their advancement and valuation increasingly depend on specific lead assets entering clinical trials. At this stage, investors expect early human proof of mechanism, often in oncology, immunology, or rare disease indications, rather than platform novelty alone.

Public and recently acquired companies sit at the opposite end of this progression. Here, innovation is less about inventing new delivery modalities and more about scaling, optimizing, and expanding technologies that have already demonstrated clinical feasibility. Abivax, CureVac, and Arcturus Therapeutics exemplify this phase, with efforts focused on dose optimization, manufacturability, and regulatory execution across late-stage or commercial programs.

The bankruptcy cases illustrate the risks inherent at each stage of this continuum. Gritstone Bio advanced self-amplifying RNA cancer vaccines into late-stage clinical testing, but insufficient efficacy ultimately undermined its platform thesis. VaxEquity, despite early clinical progress and a strategic partnership, entered liquidation following shifts in strategic priorities and funding support. Karma Biotechnologies, which remained preclinical, appears to have dissolved after failing to secure follow-on financing. Together, these outcomes highlight that neither advanced clinical stage nor novel platform science alone guarantees durability.

Taken together, these patterns reinforce a consistent theme: funding stage closely mirrors both clinical position and the type of innovation being pursued. Seed-stage companies concentrate on foundational platform science, Series A companies test clinically tractable mechanisms, Series B companies advance asset-driven programs toward proof in humans, and public or acquired companies focus on execution at scale. In the RNA and LNP space—where delivery, chemistry, and biology are tightly coupled—this progression provides a useful framework for understanding how technological innovation translates into clinical and financial outcomes.

Deal Dynamics and Investment Patterns

To complement the analysis of clinical maturity and platform development, we next examined deal activity and capital deployment across RNA and lipid nanoparticle-focused biotechnology startups. Using PitchBook data, we analyzed deal counts by year and total capital raised by year to understand how investment patterns in RNA and LNP therapeutics have evolved over time (Figure 6). In biotechnology, deal activity and capital concentration are often used as indicators of technical validation and strategic relevance. Viewed together, these metrics provide insight into how enthusiasm for RNA and LNP platforms has shifted as programs have moved from early platform exploration toward clinical and commercial execution.

Figure 6. Deal activity and capital deployment in RNA and LNP startups over time. Bar charts showing (top) annual deal counts and (bottom) total capital raised by year among RNA and LNP-focused biotechnology startups identified using PitchBook. Deals are categorized by transaction type, including venture capital financings, corporate/strategic mergers and acquisitions, and IPO or liquidity events.

Across the past decade, deal activity increased steadily from 2016 through the pandemic years, with a clear inflection in 2020–2021 as mRNA–LNP vaccines proved clinically and commercially viable. Most transactions during this period are traditional venture rounds, while large corporate acquisitions remain relatively rare. Although deal counts stabilize after 2021, they remain well above pre-pandemic levels, indicating sustained interest in RNA delivery beyond COVID-19. Capital deployed follows a different pattern, driven primarily by a small number of large transactions rather than deal volume, explaining the pronounced spike in 2025 driven by strategic consolidation.

The four major transactions in 2025—Capstan Therapeutics, Orbital Therapeutics, Verve Therapeutics, and CureVac—account for more than $6.8 billion in aggregate value and highlight where pharmaceutical interest is concentrating. Capstan Therapeutics was acquired by AbbVie for $2.1 billion, anchored by its lead program CPTX2309, an LNP-delivered in vivo CAR-T therapy targeting CD8 T cells for autoimmune disease. At the time of acquisition, CPTX2309 was in a Phase I clinical trial, demonstrating the feasibility of programming immune cells directly in patients without ex vivo manufacturing.

Orbital Therapeutics was acquired by Bristol Myers Squibb for $1.5 billion, reflecting growing confidence in circular RNA as a next-generation RNA modality. Orbital’s lead programs, including OTX-201, were preclinical and designed to enable sustained CAR expression in vivo using circular RNA constructs. The transaction underscores strategic interest in RNA architectures that extend expression durability beyond conventional mRNA while remaining compatible with lipid nanoparticle delivery.

Verve Therapeutics, acquired by Eli Lilly for approximately $1.3 billion, represents one of the most clinically advanced examples of LNP-enabled in vivo genome editing. Its lead assets, VERVE-101 and VERVE-102, were in Phase I clinical trials, targeting permanent reduction of LDL cholesterol through base editing in hepatocytes. This acquisition reflects confidence in liver-directed LNP delivery and the potential for one-time genetic interventions in cardiometabolic disease.

The acquisition of CureVac by BioNTech for roughly $1.25 billion reflects a complementary strategic rationale. Rather than a single breakthrough asset, CureVac contributed mature mRNA design capabilities, intellectual property, and manufacturing infrastructure, alongside multiple assets in Phase II clinical trials across infectious disease and oncology indications. This transaction highlights consolidation around established mRNA know-how and late-stage clinical programs rather than expansion into a new modality.

Even though each company is pursuing a distinct strategy—Capstan and Orbital advancing in vivo cell therapy, Verve targeting long-lasting genetic correction, and CureVac focusing on mRNA optimization and manufacturing—they all converge on the same core principle: direct manipulation of cells and tissues in vivo without reliance on ex vivo processing or complex biologics manufacturing. This shift points toward therapies that function more like programmable biological software—single-injection RNA medicines capable of reprogramming immunity, repairing genes, or driving sustained protein expression within the body. These acquisitions point to a future where in vivo engineering becomes the central value driver, and where the largest capital flows go to platforms that can turn that concept into clinically meaningful therapies.

Future Outlook

Across geography, therapeutic focus, funding trajectories, and deal activity, a coherent picture emerges of an RNA and LNP field that has moved well beyond its pandemic-era inflection point. What began as a vaccine-enabling technology has matured into a broadly applicable platform, now extending into oncology, rare and genetic disease, CNS disorders, and in vivo cell engineering. This expansion reflects parallel advances in delivery chemistry, targeting strategies, and RNA construct design, as well as a growing willingness to apply these tools to more complex biological problems.

These scientific shifts are closely mirrored in financing and deal-making patterns. Early-stage capital remains tightly aligned with platform innovation and delivery risk, while later-stage funding and acquisitions increasingly concentrate on clinically actionable programs and translational readiness. The activity in 2025 is particularly illustrative: acquisitions of Capstan, Orbital, Verve, and CureVac highlight sustained strategic interest in platforms capable of direct in vivo modulation of cells, tissues, or gene targets. Even amid broader volatility in biotech markets, these transactions signal continued confidence in RNA- and LNP-enabled modalities as long-term therapeutic engines.

At the same time, meaningful challenges remain. Achieving reliable extrahepatic delivery, scaling manufacturing, and navigating regulatory pathways for gene-modifying payloads will shape how rapidly these technologies progress from promise to practice. Taken together, the data point to a sector that is neither static nor saturated but steadily expanding in scope and ambition. The next phase of RNA medicine will likely be defined by how effectively emerging platforms translate technical sophistication into durable clinical benefit, while balancing innovation with the practical demands of safety, manufacturability, and patient access.

Written By:  Xingyu (Jasmine) Hu (PhD student in the Department of Biomedical Engineering, Boston University)